Last reviewed · How we verify
NCT03895671: PONAZA
PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS
Phase 2 trial testing Ponatinib in CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE in 40 participants. Status unknown.
1 December 2023
Quick facts
| Lead sponsor | Versailles Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 19 June 2019 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 December 2024 |
| Sites | 29 locations across France |
Drugs / interventions tested
- Ponatinib — full drug profile →
- Azacitidine (azacitidine) — full drug profile →
Conditions studied
- CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE — all drugs for CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE →
- CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS — all drugs for CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS →
Sponsor
Versailles Hospital
Who can join
18 and older, any sex, with CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE or CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project is strategy aiming to improve the survival of patients with chronic myelogenous leukemia in advanced phase and myeloid blast crisis. The basis of this strategy is to add the demethylating agent 5-Azacitidine to the tyrosine kinase inhibitor ponatinib and evaluate its activity in 2 cohorts of patients with either chronic myelogenous leukemia in advanced phase or myeloid blast crisis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.
Alves R, Gonçalves AC, Rutella S, Almeida AM, et al · · 2021 · cited 112× · PMID 34638304 · DOI 10.3390/cancers13194820 -
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Copland M. · · 2022 · cited 31× · PMID 35866251 · DOI 10.1111/bjh.18370 -
Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.
Pushpam D, Bakhshi S. · · 2020 · cited 14× · PMID 31900888 · DOI 10.1007/s40199-019-00321-z -
Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells.
Houshmand M, Kazemi A, Anjam Najmedini A, Ali MS, et al · · 2021 · cited 10× · PMID 34945101 · DOI 10.3390/jcm10245805 -
Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase.
Yohanan B, George B. · · 2022 · cited 5× · PMID 36507316 · DOI 10.1177/11795549221139357 -
An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia.
Pamuk GE, Ehrlich LA. · · 2024 · cited 4× · PMID 39518058 · DOI 10.3390/cancers16213615 -
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
Pérez-Lamas L, Díaz AS, Casterá EM, Soto MH, et al · · 2024 · cited 1× · PMID 39269475 · DOI 10.1007/s00277-024-05906-6 -
EHA2024 Hybrid Congress
· 2024
Verify or expand the search:
- PubMed search for NCT03895671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ponatinib
Trials testing the same drug.
- NCT07224100 — Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom · Phase 2 · recruiting
- NCT06813079 — Using Tumor Models to Determine Treatments · Phase 2 · not yet recruiting
- NCT06207123 — A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leuke · Phase 1, PHASE2 · recruiting
- NCT06390306 — The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP · recruiting
- NCT06175702 — Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL · not yet recruiting
Other Versailles Hospital trials
Trials by the same sponsor.
- NCT07369245 — Techniques for Activating Consciousness (TAC) for Outpatients With Moderate to Severe Alcohol Addiction · NA · not yet recruiting
- NCT07383779 — Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus · Phase 3 · not yet recruiting
- NCT06835491 — Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac · Phase 3 · recruiting
- NCT07476755 — Cross-cultural Adaptation and Validation of the French Version of the Social Media Disorder Scale for Parents in a Sampl · completed
- NCT06650813 — Adapting the FACETS Program to Sickle Cell Disease · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03895671 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Versailles Hospital
- Last refreshed: 7 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03895671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing